Dusa/Berlex Levulan Actinic Keratoses Recurrence Phase IV Study Planned
Executive Summary
Dusa has committed to a Phase IV study of the actinic keratoses treatment Levulan Kerastick to assess the long-term recurrence rate of treated lesions over a 12-month follow-up period.
You may also be interested in...
Berlex Dermatology's First U.S. Product Will Be Dusa's Levulan
Berlex will begin hiring reps in December for its new U.S. dermatology sales force, which will promote Dusa's Levulan for actinic keratoses.
Dusa Levulan Label Should Disclose Partial Responses, Advisory Panel Says
Dusa Levulan Kerastick labeling which includes a 75% partial lesion clearance response for the actinic keratoses treatment could benefit clinicians and patients, FDA's Dermatologic & Ophthalmic Drugs Advisory Committee decided Nov. 5.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011